Australian government says vaccine risk too high for people under 30

Australian government says vaccine risk too high for people under 30

The Australian government says the risk of myocarditis from a COVID booster might be greater than COVID itself — so it won’t allow people under 30 to get a fourth vaccine.

Australian government says vaccine risk too high for people under 30
Australian government says vaccine risk too high for people under 30.

“In males aged 16-40 years, it is uncertain whether the risk following COVID-19 remains higher than the risk following vaccination,” the government said.

The government considers myocarditis and pericarditis following COVID vaccination severe enough to warrant a 13-page guideline. The guideline is updated regularly. 

“The majority of cases of myocarditis reported after COVID-19 vaccines have occurred in males under 40, and the majority have occurred within 1-5 days (median 2 days) following the second dose of an mRNA vaccine. Myo/pericarditis is more common after the second dose of Moderna compared with second doses of Pfizer and AstraZeneca.”

The guidance further states that there are no studies on the long-term dangers of myocarditis following COVID vaccination. The government says most cases result in hospitalization and some in death.

Last week, Pfizer and Moderna launched clinical trials to study the long-term effects of myocarditis following vaccination with its mRNA vaccines. The launch comes roughly 18 months after the products went to market with a promise of being “safe and effective.”

NBC News reports that the Food and Drug Administration (FDA) required the drugmakers to conduct the study. It was needed as part of the emergency-use approval process that allowed the drugs to go to market before clinical trials were completed. 

In July, Ontario Chief Medical Officer Kieran Moore announced that a fourth vaccine is now available for everyone over 18. However, he said not everyone should get another vaccine due to the risk of myocarditis. 

Moore also suggested the “vaccine” is therapeutic.

“There’s always a risk to having any therapeutic versus a benefit. You want to make sure there’s a very strong benefit versus the risk. If you’re an 18-year-old healthy individual, the risk of getting hospitalized if you have no underlying medical illness is very, very low,” Moore said.

Share this story

Donate now to keep us on the front lines:

Help Keep your News Free

It's crucial we stay in touch

Big Tech wants to censor us, that’s why you need to stay in touch.

[wpp limit=6 order_by='views']

YOU MIGHT ALSO LIKE THESE...

Trending News

Canada’s top energy executives are urging the federal government to declare a “Canadian energy crisis” and overhaul regulations to ensure major infrastructure projects receive approval within six months of application.

TCS Wire

March 20, 2025

Trending News

Canadians are becoming more open to exploring private healthcare, with some ready to make the switch.

TCS Wire

March 10, 2025

Trending News

Trump has announced a one-month reprieve on some of the tariffs he imposed on Canada and Mexico just two days ago.

TCS Wire

March 6, 2025

Trending News

With Canada and the United States in a trade war, Premier Doug Ford is calling on Ontario grocery stores to signal to customers which of their products are Canadian.

Walid Tamtam

March 4, 2025

Trending News

U.S. President Donald Trump’s long-threatened tariffs on Canadian exports will be going into effect at midnight.

TCS Wire

March 3, 2025

Want to join the conversation?

Sign up now to be able to like, comment and reply to other members. A full membership to our site includes:

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. You consent to our cookies if you continue to use our website.